Bone Densitometers: Groundbreaking Technology for Detecting Bone Loss
 |
| Bone Densitometers Market |
Bone densitometers are medical devices used to measure bone mineral density (BMD). They use x-ray technology, similar to a mammogram, to create scans of the bone and precisely calculate BMD levels. The two most common types are dual-energy x-ray absorptiometry (DXA) and quantitative computed tomography (QCT).
DXA Scanning
DXA scanning is currently considered the gold standard for measuring BMD. During a DXA scan, the patient lies flat on their back on an examination table while an x-ray arm slowly passes over the body area being scanned. Scans only take a few minutes and expose the individual to a very small dose of radiation, much less than a standard chest x-ray. Bone density readings from a DXA scan are compared to the expected peak bone mass of a 30-year-old adult of the same gender and ethnicity. This comparison is used to determine a diagnosis.
QCT Scanning
QCT scanning provides a three-dimensional view of bone density and structure. During Bone Densitometers scan, multiple images are taken of the area being examined, such as the hip or spine, from different angles. A computer then uses these images to create a 3D model of the bones. One advantage of QCT scans over DXA is the ability to differentiate trabecular bone from cortical bone. Trabecular bone, found in the vertebrae and bones of the wrist and hand, tends to be more metabolically active and see greater loss during osteoporosis progression.
What Conditions are Detected?
The primary purpose of bone densitometers is to diagnose osteoporosis and assess fracture risk. Osteoporosis is a systemic skeletal disease characterized by low bone mass and structural deterioration of bone tissue, leading to an increased risk of fractures. Bone mineral density testing can also detect low bone density prior to osteoporosis, known as osteopenia. Other uses include monitoring treatment effectiveness in osteoporosis and other conditions affecting bone health like Paget's disease.
Osteoporosis Diagnosis Criteria
According to the World Health Organization (WHO), a T-score of -1.0 or above is considered normal bone density. A T-score between -1.0 and -2.5 indicates low bone mass, known as osteopenia. To receive an osteoporosis diagnosis, an individual must have a T-score of -2.5 or below in the spine, hip, or forearm. Approximately 10 million Americans over the age of 50 have osteoporosis of the hip and will face an osteoporosis-related fracture in their remaining lifetimes without proper prevention and treatment.
Fracture Risk Assessment
In addition to diagnosis, bone density tests provide valuable insight into fracture risk. The lower the T-score, the greater the risk for osteoporotic fracture, especially hip and spine fractures. Other clinical risk factors such as age, previous fractures, family history, smoking, excessive alcohol intake, low body weight, medical conditions, and medications are also considered. Individuals are stratified into low, moderate, or high-risk categories to guide treatment and lifestyle decisions. Fracture probabilities are also calculated for 5 and 10 years to help patients understand their unique situation.
Monitoring Treatment Effectiveness
Serial bone density testing is commonly performed to monitor treatment effectiveness in patients with osteoporosis or osteopenia. Follow-up scans should occur no sooner than 12-18 months after starting drug therapy to allow sufficient time for treatment response. Changes in BMD of 3-5% or more generally indicate a significant response to treatment. Larger increases or stability in density over time correspond to larger reductions in fracture risk. Tests may be repeated every 1-2 years as long as the individual remains on the same treatment regimen.
Who Needs Testing?
The following groups are at higher risk for osteoporosis and candidates for bone density testing:
- Postmenopausal women, especially those 65 and older
- Men 70 and older
- Women 45-64 or men 50-69 with risk factors for fractures
- Anyone with a fracture after age 50
- Anyone taking medications associated with bone loss (e.g. steroids)
- Those with diseases linked to bone loss such as rheumatoid arthritis
The U.S. Preventive Services Task Force recommends routine bone density screening for all women 65-85 years old and in younger women whose fracture risk is equal to or greater than that of a 65-year-old Caucasian female. Testing should generally begin no earlier than age 65 to reduce unnecessary radiation exposure and healthcare costs.
Is Bone Densitometers Safe?
Bone Densitometer is an extremely safe medical imaging procedure with very low radiation exposure. DXA scans emit between 1/10th to 1/100th of the radiation of a chest x-ray. QCT scans use more radiation but still a fraction of other CT exams. The radiation dose from one test is similar to about 3 months of natural background radiation in the average environment. Risk of any cancer or other health issues from such a tiny amount of radiation, which is carefully targeted, is considered insignificant. For patients at high risk of fractures, the benefits of fracture prevention through treatment clearly outweigh the negligible radiation risks.
Get more insights on Bone Densitometers
For Enhanced Understanding, Dive into the Report in the Language that Connects with You:-
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
Post a Comment